Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CiplaLUX:CIPLA 96 3-Year Book Growth Rate is 13.70% as of Jun. 2026, which is 1% below its 10-year median of 13.85. GuruFocus rates LUX:CIPLA with a GF Score™ of 96/100 and a GF Value™ of $20.96. The stock has 3 warning signs investors should review. Among 912 Drug Manufacturers companies, Cipla ranks better than 78.73% on this metric.
During the past 12 months, Cipla's average Book Value per Share Growth Rate was 10.40% per year.
During the past 3 years, the average Book Value per Share Growth Rate was 13.70% per year.
During the past 5 years, the average Book Value per Share Growth Rate was 13.70% per year.
During the past 10 years, the average Book Value per Share Growth Rate was 11.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
During the past 13 years, the highest 3-Year average Book Value per Share Growth Rate of Cipla was 35.20% per year. The lowest was 7.60% per year. And the median was 13.85% per year.
Cipla (LUX:CIPLA) 3-Year Book Growth Rate Explanation
Book Value per Share is the ratio of equity available to common shareholders divided by the shares outstanding. Book value per share effectively indicates a firm's net asset value on a per-share basis. It can be used by investors to gauge whether a stock price is undervalued by comparing it to the firm's market value per share. Theoretically, it is what the shareholders will receive if the company is liquidated.
Cipla 3-Year Book Growth Rate Related Terms
LUX:CIPLA vs ZTS: 3-Year Book Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's 3-Year Book Growth Rate, along with its competitors' market caps and 3-Year Book Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla 3-Year Book Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's 3-Year Book Growth Rate distribution charts can be found below:
* The bar in red indicates where Cipla's 3-Year Book Growth Rate falls into.
This is the 3-year average growth rate of Book Value per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Book Value per Share growth rate.
What does a 3-Year Book Growth Rate of 13.70% mean?
Cipla (LUX:CIPLA) has a 3-Year Book Growth Rate of 13.70% as of Jun. 2026. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cipla and its competitors. This is near median its historical median of 13.85. Over the past decade, Cipla's 3-Year Book Growth Rate has ranged from 7.60 to 35.20. According to the industry distribution chart, Cipla ranks #194 out of 912 companies in the Drug Manufacturers industry, placing it in the top 21.3%.
Is Cipla's 3-Year Book Growth Rate too high?
Cipla's current 3-Year Book Growth Rate of 13.70% is near median its 10-year median of 13.85. Over the past 10 years, this metric has ranged from a low of 7.60 to a high of 35.20. The Drug Manufacturers industry median 3-Year Book Growth Rate is 4.60. Cipla's value of 13.70% is 197.8% above this industry median. Based on the distribution chart, Cipla ranks #194 out of 912 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipla has a GF Score™ of 96/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's 3-Year Book Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #194 out of 912 companies for 3-Year Book Growth Rate. This places Cipla in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year Book Growth Rate is 4.60. Cipla's value of 13.70% is 197.8% above this benchmark. Historically, Cipla's own 3-Year Book Growth Rate has ranged from 7.60 to 35.20 over the past decade. While the company's 10-year median is 13.85 vs. the industry median of 4.60, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Book Growth Rate for a Drug Manufacturers company?
The median 3-Year Book Growth Rate among Drug Manufacturers companies is 4.60, based on 912 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Book Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Book Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current 3-Year Book Growth Rate of 13.70% is 197.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Book Growth Rate mean?
A high 3-Year Book Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Book Growth Rate is the 3-year average growth rate of Book Value per Share. View historical data for Cipla and its competitors. For the Drug Manufacturers industry, the median 3-Year Book Growth Rate is 4.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current 3-Year Book Growth Rate is 13.70%, which is near median its own 10-year median of 13.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current 3-Year Book Growth Rate of 13.70%. The stock's GF Value™ is $20.96, compared to a current price of $18.10 — trading 13.6% below its estimated fair value. The current 3-Year Book Growth Rate is 13.70%, which is near median its 10-year median of 13.85 and 197.8% above the Drug Manufacturers industry median of 4.60. Cipla's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Book Growth Rate calculated?
3-Year Book Growth Rate is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current 3-Year Book Growth Rate is 13.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 13.6% below its estimated GF Value™ of $20.96.
Key valuation signals for LUX:CIPLA:
3-Year Book Growth Rate: 13.70% (near median its 10-year median of 13.85)
GF Value™: $20.96 vs. price of $18.10 (13.6% below fair value)
Industry Position: 197.8% above the Drug Manufacturers median (#194 of 912)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is an Indian pharmaceutical company that develops, manufactures, and markets generic and branded medicines across a broad range of therapeutic areas, including respiratory, anti-retroviral, urology, cardiology, anti-infectives, and central nervous system treatments. Its portfolio spans complex generics, inhalers, biosimilars, and over-the-counter products, sold under brands such as Cipla and Cip-la. The company serves patients, healthcare professionals, hospitals, and governments through its own sales force and distribution partners. India is its largest market, supplemented by significant operations in North America, South Africa, and other emerging and regulated markets. Revenue comes primarily from pharmaceutical product sales, with growing contributions from its consumer healthcare and specialty businesses. Cipla invests in research and development and pursues growth through new product launches, partnerships, and geographic expansion.
96GF Score
Get the complete analysis for LUX:CIPLA
3-Year Book Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
